Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03361748 · OUTCOME

Number of Participants With Anti-CAR-Antibodies

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose to the end of follow up (Approximately 5 years)

What was measured

Number of Participants with Anti-CAR-Antibodies. Pre-postive is defined by last value before or on bb2121 infusion date is positive Post-positve is defined by at least one positive value post bb2121 infusion.

Analysis population: All Treated Population

Groups in this outcome

BB2121

BB2121

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
BB2121137

Reported measurements

Pre-Positive Pre-positive and post-positive

Analysis denominator · Participants

GroupSource count
BB21216
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21216Not reportedNot reportedNot reportedNot reported
Pre-Positive Pre-positive and post-negative

Analysis denominator · Participants

GroupSource count
BB21216
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21210Not reportedNot reportedNot reportedNot reported
Pre-Positive Missing post data

Analysis denominator · Participants

GroupSource count
BB21216
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21210Not reportedNot reportedNot reportedNot reported
Pre-Negative Pre-negative and post-postive

Analysis denominator · Participants

GroupSource count
BB2121130
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB212169Not reportedNot reportedNot reportedNot reported
Pre-Negative Pre-negative and post-negative

Analysis denominator · Participants

GroupSource count
BB2121130
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB212160Not reportedNot reportedNot reportedNot reported
Pre-Negative Missing post data

Analysis denominator · Participants

GroupSource count
BB2121130
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21211Not reportedNot reportedNot reportedNot reported
Missing Pre Data Post-positive

Analysis denominator · Participants

GroupSource count
BB21211
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21211Not reportedNot reportedNot reportedNot reported
Missing Pre Data post-negative

Analysis denominator · Participants

GroupSource count
BB21211
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21210Not reportedNot reportedNot reportedNot reported
Missing Pre Data missing Post Data

Analysis denominator · Participants

GroupSource count
BB21211
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
BB21210Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      units
      Participants
    title
    Pre-Positive Pre-positive and post-positive
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      units
      Participants
    title
    Pre-Positive Pre-positive and post-negative
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        6
      units
      Participants
    title
    Pre-Positive Missing post data
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        69
    denoms
    1. counts
      1. group Id
        OG000
        value
        130
      units
      Participants
    title
    Pre-Negative Pre-negative and post-postive
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        60
    denoms
    1. counts
      1. group Id
        OG000
        value
        130
      units
      Participants
    title
    Pre-Negative Pre-negative and post-negative
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    denoms
    1. counts
      1. group Id
        OG000
        value
        130
      units
      Participants
    title
    Pre-Negative Missing post data
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      units
      Participants
    title
    Missing Pre Data Post-positive
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      units
      Participants
    title
    Missing Pre Data post-negative
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    denoms
    1. counts
      1. group Id
        OG000
        value
        1
      units
      Participants
    title
    Missing Pre Data missing Post Data
denoms
  1. counts
    1. group Id
      OG000
      value
      137
    units
    Participants
description
Number of Participants with Anti-CAR-Antibodies. Pre-postive is defined by last value before or on bb2121 infusion date is positive Post-positve is defined by at least one positive value post bb2121 infusion.
groups
  1. description
    BB2121
    id
    OG000
    title
    BB2121
param Type
COUNT_OF_PARTICIPANTS
population Description
All Treated Population
reporting Status
POSTED
time Frame
From first dose to the end of follow up (Approximately 5 years)
title
Number of Participants With Anti-CAR-Antibodies
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice